Session III: NASH Trials- All things Considered

What is the ideal NASH drug? What are the challenges and opportunities in clinical trial design relative to enrollment, clinical trial end points, and stabilization of placebo response rates? This session will also cover utilization of MRE to predict fibrotic response in NASH. 

SPEAKERS

Moderators:
Naim Alkhouri, MD  
Summer Collier, MSN, FNP-BC

Presenters:

Brent A. Tetri, MD, FAASLD - Ideal NASH Drug
Arun J. Sanyal, MD, FAASLD - NASH Related Fibrosis and Cirrhosis: Phase 2/3/4 Endpoints
Stephen A. Harrison, MD, FAASLD - Patient Selection and Screen Fail Rate Mitigation (NASH and Cirrhosis)
Charles Wang, MD - Histological Assessment of Mitochondrial Pyruvate Carrier (MPC) as a Lipid Metabolic Regulator and Determination of Disease Severity in Human Non-alcoholic Hepatosteatosis
Rebecca Taub, MD - Prediction of Fibrotic Nash and Treatment with Resmetirom in Phase 3 Maestro Studies: MRI-PDFF and Magnetic Resonance Elastography
Mary E. McCarthy Rinella, MD, FAASLD - Stabilization of Placebo Response Rates in NASH and Cirrhosis Trials